162 related articles for article (PubMed ID: 11792416)
21. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
22. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
23. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.
Jorda EG; Verdaguer E; Canudas AM; Jiménez A; Bruna A; Caelles C; Bravo R; Escubedo E; Pubill D; Camarasa J; Pallàs M; Camins A
Neuropharmacology; 2003 Oct; 45(5):672-83. PubMed ID: 12941380
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
26. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
28. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
29. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
30. Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.
Takada Y; Sethi G; Sung B; Aggarwal BB
Mol Pharmacol; 2008 May; 73(5):1549-57. PubMed ID: 18287248
[TBL] [Abstract][Full Text] [Related]
31. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
Deaglio S; Canella D; Baj G; Arnulfo A; Waxman S; Malavasi F
Leuk Res; 2001 Mar; 25(3):227-35. PubMed ID: 11226519
[TBL] [Abstract][Full Text] [Related]
32. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM
Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647
[TBL] [Abstract][Full Text] [Related]
35. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
Lee HR; Chang TH; Tebalt MJ; Senderowicz AM; Szabo E
Int J Oncol; 1999 Jul; 15(1):161-6. PubMed ID: 10375610
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
37. Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation.
Puppo M; Pastorino S; Melillo G; Pezzolo A; Varesio L; Bosco MC
Clin Cancer Res; 2004 Dec; 10(24):8704-19. PubMed ID: 15623656
[TBL] [Abstract][Full Text] [Related]
38. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Oshiro MM; Landowski TH; Catlett-Falcone R; Hazlehurst LA; Huang M; Jove R; Dalton WS
Clin Cancer Res; 2001 Dec; 7(12):4262-71. PubMed ID: 11751528
[TBL] [Abstract][Full Text] [Related]
40. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
Ogata A; Chauhan D; Teoh G; Treon SP; Urashima M; Schlossman RL; Anderson KC
J Immunol; 1997 Sep; 159(5):2212-21. PubMed ID: 9278309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
